PKB (also known as c-Akt or Rac-PK) was originally identified as the transforming oncogene in a retrovirus from a spontaneous thymoma in an AKR mouse. PKB appears to be activated as a consequence of increased phosphoinositide 3-kinase (PI3K) activity in cells stimulated with mitogens. Potential targets of PKB include glycogen synthase kinase-3 and p70 ribosomal protein S6 kinase. PKB is also crucial in mediating cell survival. Activation forms of both PI3 kinase and PKB have been shown to protect from apoptosis induced by withdrawal of growth and survival factors, expression of c-myc, and detachment from extracellular matrix. GenBank M63167. The recombinant protein contains the amino acid substitution S478G with respect to this accession number. This is reported in EMBL BE 206796.
Ser/Thr Kinases: Akt Family
NM_001014431.1; NM_001014432.1; NM_005163.2
AKT serine/threonine kinase 1, AKT, PKB, RAC, PRKBA, PKB-ALPHA, RAC-ALPHA
Drug Discovery & Development
1 year at -70°C
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.